BioSpecifics Technologies Corp. Announces Online Publication in The Journal of Urology of Results from the IMPRESS Trials of XIAFLEX in Peyronie's Disease

LYNBROOK, N.Y., Feb. 4, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX® in Europe and Eurasia,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials